Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.58 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.58 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | F13A1 | P00488 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | TGM1 | P22735 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10372905 | 0.90 | MEN1 (0.62) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL10153811 | 0.90 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL30625217 | 0.87 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL29532829 | 0.86 | GRIN2B (0.67) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL1495904 | 0.86 | GRIN2B (0.67) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL25248629 | 0.85 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL28959674 | 0.85 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL401825 | 0.85 | SMN1; SMN2 (0.70) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL34466702 | 0.84 | GRIN2B (0.62) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL25256030 | 0.84 | GRIN2B (0.62) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357908-A4 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-6852738-B2 | Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| EP-1357908-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002060388-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-5849732-A | Phenol compound having antioxidative activity and the process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| CN-1165815-A | Phenol compound and process for preparing the same | TANABE SEIYAKU CO (JP) | 1997-11-26 | — | — | CN | disclosed |
| EP-0790240-A1 | Phenol-derivatives having pharmaceutical activity and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | PPARA, PPARD, PPARG | GRIN2B 2372/4885CYP2D6 3895/4885CYP2C9 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.